Document:

inmune_ex105.htm

EXHIBIT 10.5

 

ASSIGNMENT AND ASSUMPTION AGREEMENT

 

This Assignment and Assumption ("Assignment") is effective as of October 03, 2017 ("Effective Date") by and among, Immune Ventures, LLC, a Limited Liability Company formed under the laws of the State of Washington, with principal offices located at 7503 Jones Ave NW, Seattle, WA 98116 (“ASSIGNOR”) and INmune Bio Inc., a Nevada corporation, having its principal place of business at 1224 Prospect St., Suite 150, La Jolla, CA 92037 (“ASSIGNEE”).

 

BACKGROUND

 

1. University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, Pennsylvania 15260 (“University”) and ASSIGNOR entered into an Exclusive License Agreement, dated June 26, 2017, which was amended by way of the First Amendment to Exclusive License Agreement, dated September 20, 2017, each of which being collectively referred to herein as the “Exclusive License Agreement”; a true and correct copy of which is attached herewith as “Exhibit A”;

 

2. ASSIGNOR desires to assign all of its rights, obligations and liabilities under the Exclusive License Agreement to ASSIGNEE;

 

3. ASSIGNEE desires to accept and assume all of the rights, obligations and liabilities of ASSIGNOR under the Exclusive License Agreement; and

 

4. In accordance with Article 9 of the Exclusive License Agreement, such assignment and acceptance does not require prior written consent of University.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as set forth below.

 

	 
	 
	

 
	 

 

1. ASSIGNOR hereby assigns to ASSIGNEE and ASSIGNEE hereby accepts and assumes all of ASSIGNOR’s rights, obligations and liabilities under the Exclusive License Agreement.

 

2. The Assignment and any actions arising out of or relating to this Assignment shall be governed by and construed and interpreted in accordance with the laws of the state of California and the United States of America without regard to the conflict of law provisions thereof.

 

3. ASSIGNOR paid $31,640 (“Costs”) to University of Pittsburgh on August 18, 2017. ASSIGNEE hereby agrees to reimburse said Costs in full by issuing shares at $1.50 per share for 21,094 shares.

 

IN WITNESS WHEREOF the parties hereto have executed this Assignment as of the Effective Date set forth above.

 

 

	
ASSIGNOR
	 	
ASSIGNEE
	 
	
 
	
 
	
 
	
 
	
 

	
By:
	/s/ Raymond J. Tesi	 	By:	/s/ David J. Moss	 
	
Print Name:
	
Raymond J. Tesi
	 	Print Name: 	David J. Moss	 
	
Title:
	
President and CEO  
	 	
Title:
	Principle	 
	
Date:
	
October 3, 2017
	
 
	
Date: 
	
October 3, 2017inmune_ex106.htm

EXHIBIT 10.6

 

EXCLUSIVE LICENSE AGREEMENT

 

This Agreement is made and entered into as of June 26, 2017 (“Effective Date”), by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non- profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, Pennsylvania 15260 (“University”), and Immune Ventures, LLC, with its principal business at 7503 Jones Ave NW, Seattle, WA 98117 (“Licensee”).

 

WHEREAS, University has represented to Licensee that it is the owner by assignment from the inventors of certain Patent Rights, entitled “Cancer prevention and therapy by exclusion of soluble tumor necrosis factor,” developed by Drs. Lazar N. Vujanovic and Nikola L. Vujanovic of University faculty, and University has the right to grant licenses under such Patent Rights;

 

WHEREAS, University desires to have the Patent Rights utilized in the public interest;

 

WHEREAS, Licensee has represented to University, to induce University to enter into this Agreement, that Licensee is experienced in the development, production, manufacture, marketing and sale of products and/or the use of similar products to the Licensed Technology and that Licensee shall commit itself to a thorough, vigorous and diligent program of exploiting the Patent Rights so that public utilization results therefrom; and

 

WHEREAS, Licensee desires to obtain a license under the Patent Rights upon the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto, intending to be legally bound, agree as follows:

 

	 
	 
	

 
	 

 

ARTICLE 1 – DEFINITIONS

 

For purposes of this Agreement, the following words and phrases shall have the following meanings:

 

	1.1	“Affiliate” shall mean, with respect to University, any clinical or research entity that is operated or managed as a facility under the UPMC Health System, whether or not owned by University.
	
 
	
 

	1.2	“Field” shall mean treatment and/or prevention of cancer.
	
 
	
 

	1.3	“Licensee” shall mean Immune Venture, LLC, and all entities at least fifty percent (50%) owned or controlled by Immune Venture, LLC.
	
 
	
 

	1.4	“Licensed Technology” shall mean any product or part thereof or service which is:

 

	
 
	(a)	Covered in whole or in part by a Valid Claim contained in the Patent Rights in the country in which any such product or part thereof is made, used or sold or in which any such service is used or sold; or
	
 
	
 
	
 

	
 
	(b)	Manufactured by using a process or is employed to practice a process which is covered in a Valid Claim contained in the Patent Rights in the country in which any such process that is included in Licensed Technology is used or in which such product or part thereof or service is used or sold.

 

	
1.5 
	
“Net Sales” shall mean Licensee’s and any sublicensee’s invoice price for products or services included in Licensed Technology and produced hereunder less the sum of the following:

	
 
	
 
	
 

	
 
	(a)	Actual cost of freight charges or freight absorption, separately stated in such invoice;
	
 
	
 
	
 

	
 
	(b)	Actual trade, quantity or cash discounts allowed, if any; and
	
 
	
 
	
 

	
 
	(c)	Sales taxes, tariff duties and/or use taxes separately stated on each invoice.
	
 
	
 
	
 

	
1.6 
	
“Non-Commercial Education and Research Purposes” shall mean use of Patent Rights (including distribution of biological materials covered by the Patent Rights) in the Field for academic research or other not-for-profit scholarly purposes which are undertaken at a nonprofit or governmental institution that does not use the Patent Rights in the production or manufacture of products for sale or the performance of services for a fee.

 

	 
	2
	

 
	 

 

	1.7	“Non-Royalty Sublicense Income” shall mean execution fees, maintenance fees, milestone fees and all other non-royalty payments received by Licensee from its sublicensees pursuant to any sublicense granted pursuant to Section 2.3 hereunder.
	
 
	
 

	1.8	“Patent Rights” shall mean University intellectual property described below and assigned to University:

 

	
 
	(a)	The United States and foreign patents and/or patent applications listed in Exhibit A;
	
 
	
 
	
 

	
 
	(b)	United States and foreign patents issued from the applications listed in Exhibit A and from divisionals and continuations of these applications; and
	
 
	
 
	
 

	
 
	(c)	Claims of U.S. and foreign continuation and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed in Exhibit A.

 

	1.9	“Territory” shall mean worldwide.
	
 
	
 

	1.10	“Valid Claim” means a claim of: (a) an issued and unexpired patent included within the Patent Rights which has not been held permanently revoked, unenforceable, unpatentable or invalid by a final, unreversed, and unappealable decision of a court or other governmental body of competent jurisdiction, has been irretrievably abandoned or disclaimed, or has otherwise been finally admitted or finally determined by the relevant governmental authority to be invalid, unpatentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise; or (b) a pending claim of a patent application within the Patent Rights to the extent the claim continues to be prosecuted in good faith and has not been abandoned or finally rejected without the possibility of appeal or refiling.

 

	 
	3
	

 
	 

 

ARTICLE 2 - GRANT

 

	2.1	Subject to the terms and conditions of this Agreement, University hereby grants to Licensee, the right and exclusive license in the Territory, subject to the limitations disclosed in this Section and Section 2.2, to make, have made, use and sell the Licensed Technology in the Field and to practice under the Patent Rights in the Field for the Term set forth in Article 10 below. University reserves the royalty-free, nonexclusive right to practice under the Patent Rights and to use the Licensed Technology for Non-Commercial Education and Research Purposes.
	
 
	
 

	2.2	The license granted hereby is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. §200, et seq. Pursuant to this law, the United States government may have acquired a nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the Patent Rights throughout the world. Pursuant to 35 U.S.C. §200, et seq. Licensed Technology produced for sale in the United States shall be substantially manufactured in the United States (unless a waiver under 35 U.S.C. §204 is granted by the appropriate United States government agencies).
	
 
	
 

	2.3	Licensee shall have the right to enter into sublicensing arrangements for the rights, privileges and licenses granted hereunder upon prior written approval of each sublicensee by University, except that sublicensees shall not have rights to sublicense. Such sublicense agreements shall include a royalty rate upon sublicense Net Sales in an amount at least equal to the rate set forth in Section 4.l(c). Rights of any sublicensee shall terminate upon termination of this Agreement.
	
 
	
 

	2.4	Licensee agrees that any sublicense granted by it shall provide that the obligations to University of Articles 2, 7, 8, 9, 10, and 13 of this Agreement shall be binding upon the sublicensee as if it were party to this Agreement. Each sublicense granted by Licensee pursuant to this Agreement shall include an audit right by University of sublicensee of the same scope as provided in Section 5.2 with respect to Licensee.

 

	 
	4
	

 
	 

 

	2.5	Licensee agrees to forward to University a copy of any and all sublicense agreements promptly upon execution thereof, but in no event later than thirty (30) days after each such sublicense agreement has been executed by both parties thereto.
	
 
	
 

	2.6	The license granted hereunder shall not be construed to confer any rights upon Licensee by implication, estoppel or otherwise as to any intellectual property not specifically set forth in Exhibit A hereof.

 
ARTICLE 3 – DUE DILIGENCE

 

	
3.1 
	
Licensee shall use its best efforts to bring the Licensed Technology to market as soon as practicable, consistent with sound and reasonable business practice and judgment, and to continue active, diligent marketing efforts for the Licensed Technology throughout the Term of this Agreement.

	
 
	
 
	
 

	
3.2 
	
In addition, Licensee shall adhere to each of the following milestones:

	
 
	
 
	
 

	
 
	(a)	File an IND or foreign equivalent on Licensed Technology within five (5) years of the Effective Date of this Agreement;
	
 
	
 
	
 

	
 
	(b)	Dose the first patient in a Phase II Clinical Trial or foreign equivalent using the Licensed Technology within seven (7) years of the Effective Date of this Agreement; and
	
 
	
 
	
 

	
 
	(c)	Obtaining marketing authorization from the FDA or foreign equivalent for a product making use of the Licensed Technology within twelve (12) years of the Effective Date of this Agreement.

 

	 
	5
	

 
	 

 

	
 
	
For a single time, if a milestone in Section 3.2 has not been completed within the timeframe allotted, through no fault of Licensee, and following Commercially Reasonable Best Efforts of Licensee to meet such milestone, Licensee may request in writing from the University a six (6) month extension to meet such milestone and subsequent timeframes relying upon meeting such milestone (“First Request”), and University approval of such First Request shall not be unreasonably withheld. If after the First Request the milestone is missed a second time or another milestone is missed, through no fault of Licensee, and following Commercially Reasonable Best Efforts of Licensee to meet such milestone, Licensee request, in writing, a second extension to meet such milestone and subsequent timeframes relying upon meeting such milestone (“Second Request”), and Licensee shall be deemed to have fulfilled the milestone requirement if Licensee makes a penalty payment of Fifty Thousand Dollars ($50,000). In such case, in addition to the penalty payment required, Licensee and University shall negotiate a new time for attainment of such missed milestone and subsequent timeframes relying upon the meeting of a previous milestone will also be adjusted. If after the First Request or Second Request Licensee fails to meet any revised milestone date, University may terminate this Agreement in accordance with Section 10.2, and upon termination all rights and interest to the Patent Rights and all other rights granted by University pursuant to Section 2.1 shall revert to University.

	
 
	
 

	3.3	Licensee shall notify University in writing of the achievement of each milestone within thirty (30) days upon the achievement of the respective milestone.
	
 
	
 

	3.4	Licensee’s failure to perform in accordance with Section 3.1 or to fulfill on a timely basis any one of the milestones set forth in Section 3.2 hereof shall be grounds for University to terminate this Agreement and upon termination all rights and interest to the Licensed Technology and Patent Rights shall revert to University.

 

ARTICLE 4 – LICENSE CONSIDERATION

 

	
4.1
	
In consideration of the rights, privileges and license granted by University hereunder, Licensee shall pay royalties and other monetary consideration as follows:

	
 
	
 
	
 

	
 
	(a)	Initial license fee, nonrefundable and noncreditable against royalties, of Fifteen Thousand Dollars ($15,000) due immediately and payable within ten (10) business days from the Effective Date of this Agreement;
	
 
	
 
	
 

	
 
	(b)	Annual maintenance fees, non-refundable, non-creditable, and not to be prorated against any other payment or royalties due, in the following amounts until the first Net Sales occur:

 

	 
	6
	

 
	 

 

(i) Five Thousand Dollars ($5,000) due on the first anniversary of the Effective Date through the fifth anniversary of the Effective Date;

 

(ii) Ten Thousand Dollars ($10,000) due on the sixth anniversary of the Effective Date and the seventh anniversary of the Effective Date; and

 

(iii) Twenty-five Thousand Dollars ($25,000) due on the eight anniversary of the Effective Date and annually thereafter until First Commercial Sale.

 

	
 
		Notwithstanding the above, in the event that milestone 3.2(a) is not achieved prior to the tenth anniversary of the Effective Date of this Agreement, the annual maintenance fee schedule pursuant to this Section 4.1(b) shall be increased to Fifty Thousand Dollars ($50,000) due on the tenth anniversary of the Effective Date and annually thereafter until First Commercial Sale.
	
 
	
 
	
 

	
 
	(c)	Royalties in an amount equal to two and one half percent (2.5%) of Net Sales due each calendar quarter. In the event that Licensee is required to license intellectual property rights owned by a third party to make, use, or sell Licensed Technology in the Field or practice the Patent Rights in the Field in order to avoid infringing the patent or other intellectual property rights of such third party, then Licensee shall be entitled to a credit of such third party royalties against royalties due to University under this Section 4.1(c) provided that in no event shall the effective royalty rate applicable to Net Sales in the Field be less than one and twenty five hundredths percent (1.25%),
	
 
	
 
	
 

	
 
	(d)	Four separate Milestone payments, which shall be non-refundable and non- creditable against royalties, as follows:

 

(i) Fifty Thousand Dollars ($50,000) due upon the dosing of the first patient in a clinical trial under an IND or foreign equivalent on the Licensed Technology; 

 

	 
	7
	

 
	 

 

(ii) Five Hundred Thousand Dollars ($500,000) due upon dosing of the first patient in a Phase III or foreign equivalent clinical trial using Licensed Technology; and

 

(iv) One-Million Two-Hundred Fifty Thousand Dollars ($1,250,000) due upon First Commercial Sale of Licensed Technology.

 

	
 
	(e)	Beginning with the first Net Sales, a minimum annual royalty in the following amounts per calendar year, but only to the extent such minimum royalty is greater than the aggregate annual royalty computed in accordance with Section 4.1(c) above;

 

(i) Fifty Thousand Dollars ($50,000) on the First year through the Second year of Net Sales;

 

(ii) One Hundred Thousand Dollars ($100,000) on the Third year through the Fifth year of Net Sales; and

 

(iii) One Hundred Fifty Thousand Dollars ($150,000) on the Sixth year and annually thereafter of Net Sales.

 

	
 
	(f)	A share of Non-Royalty Sublicense Income of:
	
 
	
 
	
 

	
 
	
 
	
(i) Twenty percent (20%) if the Sublicense Income is derived from a sublicense agreement executed prior to the due diligence milestone under Section 3.2(a);

 

(ii) Fifteen percent (15%) if the Sublicense Income is derived from a sublicense agreement executed after the due diligence milestone under Section 3.2(a) and prior to the due diligence milestone under Section 3.2(b); or

 

(iii) Ten percent (10%) if the Sublicense Income is derived from a sublicense agreement executed after the due diligence milestone under Section 3.2(b) and prior to the due diligence milestone under Section 3.2(c).

 

	 
	8
	

 
	 

 

	4.2	All payments pursuant to this Agreement shall be made by check or by wire transfer in United States Dollars without deduction or exchange, collection or other charges and directed to the address, or in the case of wire transfer, to the bank set forth in Article 11. Annual maintenance fees pursuant to Section 4.1(b) hereof shall be paid on the anniversary of the Effective Date of the calendar year in which they are due. Royalty payments pursuant to Section 4.1(c) hereof shall be paid within thirty (30) days after each March 31, June 30, September 30 and December 31. Milestone payments pursuant to Section 4.1(d) shall be paid within thirty (30) days of milestone event date. Minimum annual royalties pursuant to Section 4.1(e) shall be paid by January 30 following the calendar year in which they are due. Non-Royalty Sublicense Income payments pursuant to Section 4.1(f) hereof shall by paid within thirty (30) days after receipt of payment by Licensee from sublicense.
	
 
	
 

	4.3	Taxes imposed by any foreign governmental agency on any payment to be made to University by Licensee shall be paid by Licensee without deduction from any payment due to University hereunder.
	
 
	
 

	4.4	The balance of any payments pursuant to this Agreement, including those specified in Section 6.2, which are overdue shall bear interest, compounded monthly, calculated from the due date until payment is received at the rate of eight percent (8%) per annum. Payment of such interest by Licensee shall not negate or waive the right of University to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. Licensee shall reimburse University for any costs and expenses incurred in connection with collecting any overdue balance of payments with respect to Licensee’s payment and reimbursement obligations under this Agreement, including the costs of engaging counsel or a collection agency for such purpose.
	
 
	
 

	4.5	Licensee shall sell products and/or services resulting from Licensed Technology to University and its Affiliates upon request at such price(s) and on such terms and conditions as such products and/or processes are made available to Licensee’s most favored customer.

 

	 
	9
	

 
	 

 

ARTICLE 5 – REPORTS AND AUDIT

 

	
5.1
	
Within thirty (30) days after each March 31, June 30, September 30 and December 31 of each year during the term of this Agreement beginning in the year of the first commercial sale of Licensed Technology, Licensee shall deliver to University true, accurate and detailed reports of the following information in a form as illustrated in Exhibit B:

	
 
	
 
	
 

	
 
	(a)	Number of Licensed Technology products manufactured and sold by Licensee and all sublicensees;
	
 
	
 
	
 

	
 
	(b)	Total billings for all such products;
	
 
	
 
	
 

	
 
	(c)	Accounting for all Licensed Technology services used or sold by Licensee and all sublicensees;
	
 
	
 
	
 

	
 
	(d)	Deductions set forth in Section 1.5;
	
 
	
 
	
 

	
 
	(e)	Total royalties due;
	
 
	
 
	
 

	
 
	(f)	Name and addresses of sublicensees; and
	
 
	
 
	
 

	
 
	(g)	Total Non-Royalty Sublicense Income received during such calendar quarter and total amount of payment due pursuant to Section 4.1(e).
	
 
	
 
	
 

	
5.2 
	
Licensee shall keep full, true and accurate books of account, in accordance with generally accepted accounting principles, containing all information that may be necessary for the purpose of showing the amounts payable to University hereunder. Such books of account shall be kept at Licensee’s principal place of business. Such books of account shall be open at all reasonable times for three (3) years following the end of the calendar year to which they pertain, and for three (3) years after the expiration or termination of this Agreement, for inspection by University or its agents for the purpose of verifying Licensee’s royalty statement or compliance in other respects with this Agreement. The fees and expenses of University’s representatives shall be borne by University; however, if an error of more than five percent (5%) of the total payments due or owing for any year is discovered, then Licensee shall bear University’s fees and expenses.

 

	 
	10
	

 
	 

 

	5.3	No later than sixty (60) days after December 31 of each calendar year during the term of this Agreement, Licensee shall provide to University a written annual progress report, as illustrated in Exhibit C, describing Licensee’s progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceding twelve-month period ending December 31.
	
 
	
 

	5.4	Notwithstanding the above, University shall have the right, on an annual basis during the term of this Agreement and for three (3) years after the expiration or termination of this Agreement, to inspect technical and other information from Licensee sufficient to evidence whether and to what extent Licensee is: (a) practicing the Patent Rights and/or other University property licensed hereunder; and (b) meeting its diligence obligations under Article 3, above.
	
 
	
 

	5.5 	Licensee shall report to the University the date of the first commercial sale of a Licensed Technology within sixty (60) days of occurrence in each country.

 

ARTICLE 6 – PATENT PROSECUTION

 

	6.1	University has or shall apply for, seek prompt issuance of and maintain during the term of this Agreement the Patent Rights in the United States and in such foreign countries as may be designated by Licensee in a written notice to University within a reasonable time in advance of the required foreign filing dates. Licensee shall have the opportunity to advise and cooperate with University in the prosecution, filing and maintenance of such patents. Licensee shall notify University immediately if, at any time during the term of this Agreement, Licensee or any of its sublicensees does not qualify as a “small entity” as provided by the United States Patent and Trademark Office.
	
 
	
 

	6.2	All fees and costs, including attorneys’ fees, relating to the filing, prosecution, maintenance, and post grant proceedings relating to the Patent Rights shall be the responsibility of Licensee, whether incurred prior to or after the Effective Date. Such fees and costs incurred by University prior to the Effective Date in the amount of $15,331 (“Pre- agreement Expenses”) are due on the Effective Date and shall be paid by Licensee to University within ten (10) business days of the Effective Date. Fees and costs incurred after the Effective Date, or fees and costs incurred before the Effective Date which are not included in the Pre-agreement Expenses stated above, shall be paid by Licensee within thirty (30) days after receipt of University’s invoice therefor. Additionally, Licensee shall be liable to University for all of University’s out-of-pocket filing, prosecution, and maintenance costs (including all attorneys’ fees and costs), for any and all patent prosecution and maintenance actions that will be taken by patent counsel after the term of this Agreement but in response to any instructions that were sent during the term of this Agreement from University to patent counsel relating to the Patent Rights. Payments pursuant to this Section 6.2 are not creditable against royalties or any other payment due to University under this Agreement.

 

	 
	11
	

 
	 

 

ARTICLE 7 – INFRINGEMENT ACTIONS

 

	7.1	Licensee shall inform University promptly in writing of any alleged infringement of the Patent Rights by a third party and of any available evidence thereof.
	
 
	
 

	7.2	During the term of this Agreement, Licensee shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the Patent Rights in the Field and in the Territory if Licensee has notified University in writing of its intent to prosecute; provided, however, that such right to bring such an infringement action shall remain in effect only for so long as the license granted herein remains exclusive. In furtherance of such right, University hereby agrees that Licensee may include University as a party plaintiff in any such suit, without expense to University. The total cost of any such infringement action commenced or defended solely by Licensee shall be borne by Licensee and University shall receive a percentage of any recovery or damages for past infringement derived therefrom which is equal to the percentage royalty due University under Article 4. Licensee shall indemnify University against any order for costs that may be made against University in such proceedings.
	
 
	
 

	7.3	If within six (6) months after having been notified of any alleged infringement, Licensee shall have been unsuccessful in persuading the alleged infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, or if Licensee shall notify University at any time prior thereto of its intention not to bring suit against any alleged infringer, then, and in those events only, University shall have the right, but shall not be obligated, to prosecute at its own expense any infringement of the Patent Rights, and University may, for such purposes, use the name of Licensee as party plaintiff. University shall bear all costs and expenses of any such suit. In any settlement or other conclusion, by litigation or otherwise, University shall keep any recovery or damages for past infringement derived therefrom.

 

	 
	12
	

 
	 

 

	7.4	In the event that a declaratory judgment action alleging invalidity or infringement of any of the Patent Rights shall be brought against University, Licensee, at its option, shall have the right, within thirty (30) days after commencement of such action, to intervene and take over the sole defense of the action at its own expense.
	
 
	
 

	7.5	In any infringement suit either party may institute to enforce the Patent Rights pursuant to this Agreement, the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, information, samples, specimens, and other evidence upon request.

 

ARTICLE 8 – INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY

 

	8.1	Licensee shall at all times during the term of this Agreement and thereafter indemnify, defend and hold University, its trustees, officers, faculty members, employees and affiliates (“Indemnified Parties”) harmless against all claims and expenses, including legal expenses and reasonable attorneys’ fees, arising out of the death of or injury to any person or persons or out of any damage to property or the environment, and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from: (i) the production, manufacture, sale, use, lease, consumption or advertisement of the Licensed Technology, (ii) the practice by Licensee or sublicensee of the Patent Rights; or (iii) arising from or relating to this License Agreement. Licensee shall provide this defense and indemnity whether or not any Indemnified Party, either jointly or severally, is named as a party defendant and whether or not any Indemnified Party is alleged to be negligent or otherwise responsible for any injuries to person or property. The obligation of Licensee to defend and indemnify as set forth herein shall survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement.

 

	 
	13
	

 
	 

 

	8.2	Licensee shall obtain and carry in full force and effect liability insurance which shall protect Licensee and University in regard to events covered by Section 8.1 above, as provided below:

 

	
 
	
 
	
COVERAGE 
	
LIMITS

	
 
	
 
	
 
	
 

	
 
	
(a)
	
Commercial General Liability, including, but not limited to,
	
$1,000,000 Combined Single

	
 
	
 
	
Products, Contractual, Fire, Legal and Personal Injury
	
Limits for Bodily Injury and Property Damage

	
 
	
 
		
	
 
	
(b)
	
Products Liability
	
$5,000,000

 

		The University of Pittsburgh is to be named as an additional insured with respect to insurance policies identified in Sections 8.2(a) and 8.2(b) above. Certificates of insurance evidencing the coverage required above shall be filed with University’s Innovation Institute, 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, PA 15260, no later than ten (10) days after execution of this Agreement and on or before July 1 of each subsequent year during the Term of this Agreement. Such certificates shall provide that the insurer will give University not less than thirty (30) days advance written notice of any material changes in or cancellation of coverage.

 

	 
	14
	

 
	 

 

	8.3	 UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATION AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT THAT IS MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE SALES) WHICH IS LICENSED TECHNOLOGY HEREUNDER.

 

ARTICLE 9 – ASSIGNMENT

 

		This Agreement is not assignable without the prior written consent of the other Party, which shall not be unreasonably withheld, delayed or conditioned; and any attempt to do so shall be null and void; provided however, that Licensee may assign this Agreement without the University’s prior written consent to INmune Bio, Inc., a Nevada Corporation in connection with a merger or consolidation or the transfer of all or substantially all of the assets or business of Licensee to which this Agreement relates, provided that INmune Bio, Inc. agrees in writing in advance of such assignment to be bound by the terms of this Agreement to the same extent as Licensee in advance of such assignment, and the assumption agreement is promptly delivered to University.

 

ARTICLE 10 – TERM AND TERMINATION

 

	10.1	Term. The term of this Agreement shall be the earlier of: 20 years from the Effective Date of this Agreement; the expiration of the last claim of the Patent Rights; termination pursuant to Section 10.2 and 10.3 below.

 

	 
	15
	

 
	 

 

	
10.2
	
University shall have the right to terminate this Agreement, upon written notice, if:

	
 
	
 
	
 

	
 
	(a)	Licensee defaults in the performance of any of the obligations herein contained and such default has not been cured within sixty( 60) days after receiving written notice thereof from University; or
	
 
	
 
	
 

	
 
	(b)	Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors.
	
 
	
 
	
 

	
10.3 
	
Licensee may terminate this Agreement upon three (3) months prior written notice to University and upon payment of all amounts accrued or due to the University through the effective date of termination, including patent cost reimbursement pursuant to Section 6.2 hereof.

	
 
	
 
	
 

	
10.4 
	
Upon termination of this Agreement, neither party shall be released from any obligation that accrued prior to the effective date of such termination. Licensee and any sublicensee may, however, after the effective date of such termination, sell all Licensed Technology which Licensee produced prior to the effective date of such termination, provided that Licensee shall pay to University the royalties thereon as required by Article 4 hereof and submit the reports required by Article 5 hereof.

 

ARTICLE 11 – NOTICES

 

	11.1	Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed to the address below or as either party shall designate by written notice to the other party, or if in accordance with Section 11.3.

 

In the case of University:

 

Vice Chancellor for Technology Management and Commercialization Innovation Institute

University of Pittsburgh

1st Floor Gardner Steel Conference Center

130 Thackeray Avenue

Pittsburgh, PA 15260

 

	 
	16
	

 
	 

 

In the case of Licensee:

RJ Tesi MD Immune Ventures

7503 Jones Ave, NW

Seattle, WA 98117

 

	11.2	Any payments to University hereunder by wire transfer shall be directed as follows: 

 

Bank: Mellon Bank, NA, Pittsburgh, PA

ABA Routing No.: 043000261-University of Pittsburgh

Account No.: 0015510

Mellon SWIFT Code: MELNUS3P (international transfers)

Reference Code: Office of Technology Management, Accountant - otmfinbx@pitt.edu - (412) 648-2226

 

	
 
	
The Licensee shall be responsible for all applicable fees and costs relating to any wire transfer, to include translation fees, without any deduction of such fees from amounts due to the University pursuant to this Agreement.

	
 
	
 

	11.3	All invoices to Licensee generated by University under this Agreement will be sent electronically, via e-mail, in PDF format, unless instructed otherwise by Licensee in writing.

 

ARTICLE 12 – AMENDMENT, MODIFICATION

 

This Agreement may not be amended or modified except by the execution of a written instrument signed by the University’s Executive Vice Chancellor, or its successor and/or designated University employee having signatory authority, and Licensee’s CEO. In connection with any agreed upon amendment or modification of this Agreement pursuant to this Article 12, Licensee shall be required to pay an Amendment Fee.

 

	 
	17
	

 
	 

 

ARTICLE 13 – MISCELLANEOUS

 

	13.1	This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania. The forum for any action relating to this Agreement, including those brought against individuals such as University employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the United States District Court for the Western District of Pennsylvania.
	
 
	
 

	13.2	The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement.
	
 
	
 

	13.3	The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult, with their legal counsel and/or other advisors with respect to the Patent Rights, Licensed Technology, and the terms of this Agreement.
	
 
	
 

	13.4	The parties agree that this Agreement constitutes an arm’s length business transaction and does not create a fiduciary relationship.
	
 
	
 

	13.5	Nothing contained in this Agreement shall be construed as conferring upon either party any right to use in advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of the other party, including any contraction, abbreviation, or simulation of any of the foregoing. Without the express written approval of the other party, neither party shall use any designation of the other party in any promotional activity associated with this Agreement or the Licensed Technology. Neither party shall issue any press release or make any public statement in regard to this Agreement without the prior written approval of the other party.
	
 
	
 

	13.6	Licensee agrees that with respect to the performance of this Agreement or the practice of the rights granted by the University hereunder, it shall comply with any and all applicable United States export control laws and regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department’s Office of Foreign Asset Controls.

 

	 
	18
	

 
	 

 

	13.7	If Licensee challenges the validity or enforceability of University’s Patent Rights or University’s ownership of the Patent Rights anywhere in the world, the Licensee shall continue to pay to University all royalties and other financial obligations required under this Agreement, to include patent costs and fees. If any such challenge is unsuccessful by Licensee, the royalty rates and any non-royalty sublicense income rate set forth in Article 4.1 above shall automatically double in value, to include all royalty minimums and floors; and Licensee shall reimburse the University for all fees and costs associated with defending such action, including but not limited to attorneys fees and expert fees. The effective date of such increase in royalty rates shall be the date of the first court order or date of issuance of a re-examination certificate (or foreign equivalents thereof) declaring any claim of the Patent Rights as valid or enforceable. Within thirty (30) days prior to filing any such challenge, Licensee shall provide the University with written notice of its intent to make such challenge detailing its allegation(s) along with specific and detailed facts supporting those allegations of invalidity or unenforceability of University’s Patent Rights.
	
 
	
 

	13.8	If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the remaining provisions shall not in any way be affected or impaired thereby. In the event any provision is held illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as is practical, implements purposes of the provision held invalid, illegal or unenforceable.
	
 
	
 

	13.9	Failure at any time to require performance of any of the provisions herein shall not waive or diminish a party’s right thereafter to demand compliance therewith or with any other provision. Waiver of any default shall not waive any other default. A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and signed by a duly authorized officer of the party making such waiver.
	
 
	
 

	13.10	Licensee acknowledges that University is free to publish the results of the research activities of its faculty, staff and students, even though such publication may involve the Patent Rights or Licensed Technology. University agrees to submit to Licensee any proposed publication or presentation regarding the subject matter specifically described in the Patent Rights for prior review by Licensee at least thirty (30) days before its submittal for publication or its presentation. Licensee may, within thirty (30) days after receipt of such proposed publication, request that such proposed publication be delayed not more than sixty (60) days in order to allow for protection of intellectual property rights.
	
 
	
 

	
13.11
	
Licensee shall mark all Licensed Technology with applicable U.S. and foreign patent numbers in accordance with the applicable laws of the countries in which Licensed Technology is used or sold.

 

[remainder of page intentionally left blank]

 

	 
	19
	

 
	 

  

IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind the party to this Agreement and have set their hands and seals as of the date set forth on the first page hereof.

 

	 	
UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
	
	 	 	 	 
		By:	/s/ Marc S. Malandro	
	
 
	
Marc S. Malandro, Ph.D., CLP, RTTP
	 
	 	
Vice Chancellor for Technology
	 
	
 
	
Management and Commercialization
	
 

	 	 	 	 
	
 
	
IMMUNE VENTURES, LLC
	
 

	
 
	
 
	
 
	
 

	
 
	
By:
	
/s/ RJ Tesi
	
 

	
 
	
Name: RJ Tesi MD
	
 

	
 
	
Title: Principle, Immune Ventures
	
 

 

	 
	20
	

 
	 

 

EXHIBIT A

PATENT RIGHTS FOR EXCLUSIVE LICENSE AGREEMENT BETWEEN

THE UNIVERSITY OF PITTSBURGH AND IMMUNE VENTURES

 

	
Univ. Case No.
	
Application No.
	
Application Filing Date
	
Patent No.
	
Patent Issuance Date
	
Title
	
Country

	
03352
	
62/104,026
	
01/15/2015
		
 
	
CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR
	
USA

	
03352
	
62/269,839
	
12/18/2015
		
 
	
CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR
	
USA

	
3352
	
PCT/US2016/066552
	
12/14/2016
		
 
	
CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR
	
PCT

							
							
							
							
							

 

	 
	21
	

 
	 

 

EXHIBIT B

SAMPLE ROYALTY REPORT

 

Licensee name:

Reporting period:

Date of report:

 

Royalty Reporting Form

 

	
Product
	
No. units sold

(including sublicense)
	
Invoiced

price per unit
	
Gross sales
	
Allowable

deductions
	
Net sales

	
Product name
					
 

	
Product name
					
 

	
Product name
					
 

	
Product name
					
 

	
Total
					

 

	
Total net sales
	
$

	
Royalty rate
	
 

	
Royalty due
	
$

 

Total royalty due: $ ________________

 

Name and addresses of sublicensees:

 

Total non-royalty sublicense income: $ _____________________

 

Report prepared by:

Title:

Date:

 

	 
	22
	

 
	 

 

EXHIBIT C

SAMPLE PROGRESS REPORT

 

Licensee name:

Report date:

Technology title:

 

Progress Report

 

	
A.
	
Date development plan initiated and time period covered by this report

	
B.
	
Development report

	
 
	
1.
	
Activities, e.g., research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales, etc., completed since last report including the object and parameters of the development, when initiated, when completed and the results

	
 
	
2.
	
Activities currently under investigations, i.e., ongoing activities including object and parameters of such activities, when initiated, and projected date of completion

	
C.
	
Future development activities

	
 
	
1.
	
Activities to be undertaken before next report including, but not limited to, the type and object of any studies conducted and their projected starting and completion dates

	
 
	
2.
	
Estimated total development time remaining before a product will be commercialized

	
D.
	
Changes to initial development plan

	
 
	
1.
	
Reasons for change

	
 
	
2.
	
Variables that may cause additional changes

	
E.
	
Items to be provided if applicable:

	
 
	1.	Information relating to product that has become publicly available, e.g., published articles, competing products, patents, etc.
	
 
	2.	Development work being performed by third parties other than Licensee to include name of third party, reasons for use of third party, planned future use of third parties including reasons why and type of work
	
 
	3.	Update of competitive information trends in industry, government compliance, and market plan
	
 
	4.	Certify Compliance with Section 4.5

 

 

	
23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]